A First-in-Class Approach to Endometriosis Pain: What HMI-115 Just Proved

A First-in-Class Approach to Endometriosis Pain: What HMI-115 Just Proved

By, Admin 27 March 2026

Endometriosis treatment has barely evolved in decades. Most therapies suppress hormones. That works—but at a cost. Now, Hope Medicine Inc. is testing a different path.

Their drug, HMI-115, doesn’t touch sex hormones. And early results suggest that might be a big deal.

The Study at a Glance

HopeMed ran a global Phase 2 trial to test both safety and effectiveness.

Key details:

  • Study type: Randomized, double-blind, placebo-controlled
  • Patients: 142 women with moderate-to-severe endometriosis pain
  • Geographies: United States, Poland, China
  • Treatment duration: 12 weeks

HMI-115 is a monoclonal antibody that blocks the prolactin receptor—a completely new target in endometriosis.

It has already received Breakthrough Therapy Designation from National Medical Products Administration.

What the Data Actually Shows?

The interim analysis focused on the first 102 patients.

The results are hard to ignore.

Pain reduction:

  • Dysmenorrhea (menstrual pain): 42%
  • Non-menstrual pelvic pain: 50%

Both were statistically significant vs placebo.

Safety profile:

  • No treatment-related serious adverse events
  • No significant changes in:
    • Bone mineral density
    • Estradiol, LH, FSH, progesterone

What stands out:

  • Most patients maintained normal menstrual cycles
  • No peri-menopausal symptoms reported

That last point is where things get interesting.

Why This Is Different From Existing Treatments?

Most current therapies—like GnRH agonists or antagonists—work by shutting down estrogen.

That leads to:

  • Menopausal symptoms
  • Bone density loss
  • Contraceptive effects

HMI-115 avoids all three. According to Hugh Taylor: Patients have long needed a treatment that reduces pain without altering sex-steroid hormones.

And Jeffrey Jensen adds:

  • The drug preserves normal hormone levels
  • It does not disrupt the menstrual cycle
  • It could benefit women trying to conceive

That combination is rare.

A New Biological Target After 40 Years

The real innovation isn’t just efficacy. It’s the mechanism. HMI-115 targets the prolactin receptor, something no approved endometriosis drug has done before.

According to Rui-Ping Xiao: This is the first evidence that blocking prolactin signaling can treat endometriosis pain. That’s a fundamental shift. For 40 years, the field has revolved around hormones. This breaks that pattern.

What Happens Next?

HopeMed is moving fast. CEO Nathan Chen confirmed:

  • End-of-Phase 2 meetings planned with:
    • FDA
    • NMPA
  • Goal: Launch global Phase 3 trials soon

If Phase 3 confirms these results, HMI-115 could redefine treatment standards.

The Market Behind the Science

This isn’t a niche problem. Endometriosis in numbers:

  • Affects ~190 million women globally
  • Impacts ~10% of reproductive-age women
  • Linked to ~50% of infertility cases

Market size: ~$200 billion The disease goes beyond pain:

  • Chronic inflammation
  • Infertility
  • Psychological and social impact

In short: massive unmet need.

Final Take

This is still Phase 2 data. So caution is warranted. But the signal is strong:

  • Significant pain reduction
  • Clean safety profile
  • No hormonal disruption

If this holds in Phase 3, HMI-115 won’t just be another option. It could reset how endometriosis is treated.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!